GRAIL Inc. Common Stock (GRAL)

FairStock Score: 50/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for a durable business that earns cash. GRAIL's Galleri test addresses a real medical need, and revenue is moving. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $44.7M versus $35.5M in fiscal Q2 2025, the quarter ended 2025-06-30. But the company lost $110.2M in that quarter, with diluted EPS of -$2.56. For FY2025, the year ended 2025-12-31, revenue was $147.2M and net income was -$408.4M, or -$11.11 per diluted share. It has lost money each of the last four years. Trailing free cash flow is -$296.2M, a -4.7% FCF yield on the $6.3B market cap. Debt is low, with D/E 0.04, and the FairStock Altman Z-Score of 7.56 does not point to immediate solvency stress, but the FairStock Piotroski F-Score is 3/9 and ROE and ROCE are -16.12% and -12.03%. The stock closed at $140.35 on 2026-10-13, with a FairStock P/B of 2.47 and negative P/E of -14.48. A $6.3B market cap against FY2025 revenue of $147.2M is roughly 43x sales. That price assumes a very successful future. The FairStock Score is 50/100, and no Peter Lynch category applies because losses persist. The possible moat is clinical evidence, regulatory position, and screening adoption, but none of that yet shows up in profits. I would need proof of narrowing cash losses and a credible path to earnings before calling this a Graham-style bargain.

In plain English: GRAIL sells a blood test called Galleri that looks for many types of cancer early. The business is growing sales, but it still loses a lot of money and has not made a yearly profit in the last four years. At $140.35 a share, the price looks expensive compared with its sales and losses, so it is not a bargain by simple numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer